Medindia

X

Genomma Lab Internacional Announces Third Quarter 2009 Results

Tuesday, October 27, 2009 General News J E 4
Advertisement
MEXICO CITY, Oct. 26 Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended September 30, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

3Q09 Highlights (vs. 3Q08)

(1) EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.

(2) Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.

(3) As defined below.

(4) As defined below.

(5) As defined below.

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman and Chief Executive Officer, stated: "We are pleased to report Genomma Lab's third quarter 2009 results, which demonstrate outstanding growth and profitability. We are delighted to see that consumer demand for our products remained strong during the third quarter. We will remain cautious until we are sure that the economic situation, and its effect on products demand, has ended.

"We are particularly excited about the launch of Primer Nivel Por Tu Salud, our generic pharmaceuticals brand, since we believe that the market penetration of the generic pharmaceuticals industry in Mexico remains low and we plan to capitalize on the accelerated growth rates estimated for this industry in the coming years. Also, we believe that we have consolidated our business model and feel ready to enter the U.S. and Puerto Rican markets through our strategic alliance with Televisa.

"We will continue to develop and launch innovative products under premium brands, supported by our continuous advertising strategy to drive growth in revenues, earnings and cash generation."

For the complete version of this earnings report, please visit: www.genommalab.com

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

-- During the third quarter of 2009, the Company launched Primer Nivel Por Tu Salud generic pharmaceuticals brand; the launch included 167 medical prescription ("RX") and over the counter pharmaceuticals ("OTC") products. -- Also, during the third quarter, Genomma Lab signed a strategic alliance agreement with Grupo Televisa S.A.B. de C.V. (NYSE: TV) to market and distribute OTC and personal care products in the U.S. and Puerto Rico. -- Net Sales for the quarter reached Ps. 1,123.7 million, an increase of 57.9% -- EBITDA(1) increased 43.6%, to Ps. 296.8 million. This represents a 26.4% margin during the period. -- Earnings per Share(2) increased 37.5%, to Ps. 1.09. -- International Net Sales rose 295.9%, to Ps. 187.8 million. -- During the third quarter, Genomma Lab successfully launched four products under three existing brands (Base Brands(3) and Prior Year Launches(4)) as part of our line extension strategy. -- The Company also launched six products under four New Brands(5), as part of its new product launch plan during the third quarter.

SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
eBioscience Acquires Bender MedSystems; Business C...
S
ClinOps, LLC Enhances Senior Management Team With ...